EcoDrugPlus

Tyrosinase

Ensembl ID : ENSOMEG00000002663
Gene Symbol: TYR
3 Cross references
202 Possible Orthologues:

Tyrosine Hydroxylase

Ensembl ID : ENSOMEG00000023878
Gene Symbol: TH
3 Cross references
187 Possible Orthologues:

Tyrosine Kinase 2

Ensembl ID : ENSOMEG00000023955
Gene Symbol: TYK2
3 Cross references
195 Possible Orthologues:

Tyrosine Kinase With Immunoglobulin Like And Egf Like Domains 1

Ensembl ID : ENSOMEG00000008768
Gene Symbol: TIE1
3 Cross references
205 Possible Orthologues:

Tyrosine-Protein Kinase Fyn-Like

Ensembl ID : ENSOMEG00000003649
Gene Symbol: LOC112158419
3 Cross references
196 Possible Orthologues:

Tyrosine-Protein Kinase Jak2-Like

Ensembl ID : ENSOMEG00000023623
Gene Symbol: LOC112163270
3 Cross references
199 Possible Orthologues:

Tyrosine-Protein Kinase Lyn-Like

Ensembl ID : ENSOMEG00000014325
Gene Symbol: LOC112147318
3 Cross references
195 Possible Orthologues:

Tyrosine-Protein Kinase Fyna

Ensembl ID : ENSOMEG00000013551
Gene Symbol: LOC112146402
3 Cross references
191 Possible Orthologues:

Tyrosine-Protein Kinase Yes

Ensembl ID : ENSOMEG00000011251
Gene Symbol: LOC112147393
3 Cross references
206 Possible Orthologues:

Uncharacterized Loc112146978

Ensembl ID : ENSOMEG00000022463
Gene Symbol: LOC112146978
2 Cross references
196 Possible Orthologues:

Urotensin 2 Receptor

Ensembl ID : ENSOMEG00000005501
Gene Symbol: UTS2R
4 Cross references
97 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 2

Ensembl ID : ENSOMEG00000007128
Gene Symbol: AKT2
1 Cross references
210 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).